{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-015114","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.307615+00:00","generated_at":"2026-06-18T22:25:40.799929+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Longeveron appoints Wa'el Hashad as CEO effective March 1, 2023","bullets":["Wa'el Hashad named CEO, effective March 1, 2023; joins Board of Directors.","Hashad previously President & CEO of Avanir Pharmaceuticals (2017-2023).","Interim CEO Chris Min, M.D., Ph.D., returns to role as Chief Medical Officer.","Compensation: $530k annual salary, up to 70% bonus, 50,000 RSU signing bonus.","Hashad brings 35+ years experience at Amgen, Boehringer Ingelheim, Eli Lilly."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-015114","json":"https://secwatch.observer/filing/0001213900-23-015114.json","markdown":"https://secwatch.observer/filing/0001213900-23-015114.md","text":"https://secwatch.observer/filing/0001213900-23-015114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023015114/0001213900-23-015114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023015114/ea174406-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:25:40.799929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8fcc1ca95c","claim":"Wa'el Hashad was appointed as Chief Executive Officer at Longeveron Inc..","evidence_excerpt":"On February 22, 2023, the Board of Directors of Longeveron Inc. (the “Company”) appointed Mr. Wa’el Hashad to serve as the Company’s Chief Executive Officer, effective March 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023015114/0001213900-23-015114-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"cf96db0f8e","claim":"Chris Min changed role as Chief Medical Officer at Longeveron Inc..","evidence_excerpt":"Dr. Chris Min, who has been serving as interim Chief Executive Officer, will continue to serve as Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1721484/000121390023015114/0001213900-23-015114-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will continue to serve as Chief Medical Officer"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}